Pay in 4 interest-free payments of $6.02 Learn more
Ships within 48 hours · Estimated delivery Nov 1 - Nov 6
Stay informed about the regulatory landscape
Clinical Results and Weight Loss Data Retatrutide has produced some of the most impressive weight loss data seen to date: 11.5% to 16.8% weight loss in type 2 diabetes trials Up to 24% weight loss in obesity studies at 48 weeks Average loss of over 36 pounds in 40 weeks at higher doses In certain populations, including individuals with obesity and joint issues, weight loss exceeded 70 pounds over the course of a year
Medical Oversight: Licensed providers guiding prescriptions and follow-up
Further studies assessing the safety, effectiveness, and sustainability of these novel endoscopic techniques are warranted
While both GLP 1 & GIP therapy and GLP 1s are GLP-1 receptor agonists that help with weight loss, GLP 1 & GIP therapy also includes a second mechanismGIP receptor activationwhich enhances its effectiveness
